For community oncology\u2014where ACCC members are on the front lines of cancer research\u2014these tools are particularly powerful. They can help design studies that are feasible in real-world settings, more inclusive, and better aligned with the patients actually seen in community clinics.<\/p>\n\n\n\n
\n\n\n\n
Why Traditional Trial Design Falls Short<\/h2>\n\n\n\n
Classically, trial design is driven by expert opinion, limited feasibility data, and static assumptions:<\/p>\n\n\n\n
- \n
- Overly restrictive eligibility criteria<\/strong>\u00a0shrink the pool of eligible patients and slow accrual.<\/li>\n\n\n\n
- Optimistic enrollment forecasts<\/strong>\u00a0lead to missed milestones and repeated rescue amendments.<\/li>\n\n\n\n
- Underpowered or overpowered sample sizes<\/strong>\u00a0either risk inconclusive results or waste resources.<\/li>\n\n\n\n
- Sites are selected based on relationships and historical \u201cfeel\u201d<\/strong>\u00a0rather than hard performance data.<\/li>\n<\/ul>\n\n\n\n
The result: 40\u201350% of trials require at least one substantial amendment<\/strong>, many due to flawed initial design assumptions, and a high fraction terminate early for poor accrual or operational issues.<\/a><\/p>\n\n\n\n
AI and ML flip this paradigm from \u201cdesign by assumption\u201d to \u201cdesign by simulation.\u201d<\/strong><\/p>\n\n\n\n\n
![](\"https:\/\/i.postimg.cc\/pXwf13sb\/IICRS-Banner.png\")
\n<\/a>\n\n\n\n
\n\n\n\nHow Predictive Models Optimize Trial Design<\/h2>\n\n\n\n
1. Simulating Eligibility Criteria and Patient Pools<\/h3>\n\n\n\n
One of the most powerful applications of AI in design is using real-world data to test and refine inclusion and exclusion criteria before first-patient-in.<\/p>\n\n\n\n
Tools like Trial Pathfinder<\/strong> ingest large volumes of de-identified EHR and claims data from prior oncology patients to build \u201cvirtual\u201d trial cohorts.<\/a><\/p>\n\n\n\n
- \n
- The model applies the planned eligibility criteria to real patient histories.<\/li>\n\n\n\n
- It estimates how many patients at participating centers would qualify.<\/li>\n\n\n\n
- It can then iteratively \u201crelax\u201d individual criteria (e.g., a creatinine cutoff, a specific comorbidity exclusion) and simulate:\n
- \n
- How much the eligible pool grows.<\/li>\n\n\n\n
- Whether relaxing that rule materially changes overall survival curves, hazard ratios, or safety risks.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n
In landmark work, Trial Pathfinder and related approaches showed that broadening criteria based on data could double the eligible patient pool on average, without meaningfully changing hazard ratios for overall survival<\/strong>\u2014meaning many exclusions were unnecessarily restrictive.<\/a><\/p>\n\n\n\n
For community oncology, this is especially important: many traditional criteria were written around large academic centers<\/strong>, unintentionally filtering out patients with common real-world comorbidities seen in community practice. AI makes it possible to design studies that protect safety but are also realistic and inclusive.<\/strong><\/p>\n\n\n\n
\n\n\n\n2. Enrollment and Duration Forecasting<\/h3>\n\n\n\n
Even with better eligibility, planning accrual realistically is difficult. That\u2019s where predictive models such as TrialDura<\/strong> come in.<\/a>\u200b<\/p>\n\n\n\n
- \n
- TrialDura uses a\u00a0hierarchical attention transformer<\/strong>\u00a0over multimodal inputs\u2014disease area, intervention type, phase, region, eligibility complexity\u2014to predict\u00a0likely trial duration<\/strong>\u00a0and enrollment speed.<\/li>\n\n\n\n
- Trained on thousands of historical trials, it achieved\u00a0mean absolute error of ~1.0 year<\/strong>\u00a0and RMSE of ~1.39 years in trial duration prediction, outperforming simpler baselines.<\/a>\u200b<\/li>\n<\/ul>\n\n\n\n
In parallel, commercial and open tools use ML to:<\/p>\n\n\n\n
- \n
- Rank sites by\u00a0probability of high enrollment<\/strong>\u00a0based on past performance, patient mix, and operational metrics.<\/a>\u200b<\/li>\n\n\n\n
- Estimate\u00a0screen fail rates and drop-out rates<\/strong>\u00a0for a proposed protocol.<\/li>\n\n\n\n
- Simulate multiple \u201cwhat-if\u201d scenarios:\n
- \n
- Fewer sites with higher expected performance vs more sites with lower performance.<\/li>\n\n\n\n
- Different geographic mixes to improve diversity.<\/li>\n\n\n\n
- Decentralized elements (e.g., telehealth visits, local labs) to boost participation.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n
McKinsey and others report that, across portfolios, AI\/ML-enhanced site and country selection has improved identification of top-enrolling sites by 30\u201350% and accelerated enrollment by 10\u201315%<\/strong>, contributing to overall timeline compression of up to 30%.<\/strong><\/a><\/p>\n\n\n\n
For sponsors and ACCC-member programs alike, that can be the difference between a trial that languishes and one that reaches its endpoints on time.<\/p>\n\n\n\n
\n\n\n\n3. Predicting Early Termination and Design Risk<\/h3>\n\n\n\n
A 2023 study proposed a machine learning pipeline to predict the probability of early trial termination<\/strong> using public registry data from ClinicalTrials.gov.<\/a>\u200b<\/p>\n\n\n\n
- \n
- Features included sponsor type, phase, therapeutic area, inclusion complexity, geography, and more.<\/li>\n\n\n\n
- Interpretable models (e.g., gradient boosting with SHAP explanations) identified\u00a0key risk drivers<\/strong>, such as:\n
- \n
- Overly narrow indications.<\/li>\n\n\n\n
- Under-resourced geographies.<\/li>\n\n\n\n
- Complex, burdensome visit schedules.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n
The goal is not to replace human judgment, but to flag designs at high risk of failure before launch<\/strong>, so teams can:<\/p>\n\n\n\n
- \n
- Simplify visit schedules or reduce assessment burden.<\/li>\n\n\n\n
- Adjust endpoints or sample size.<\/li>\n\n\n\n
- Reconsider site mix or operational model.<\/li>\n<\/ul>\n\n\n\n
In oncology, where patient populations are often small and every eligible patient matters, avoiding a preventable early-terminated trial is a major win\u2014for both sponsors and communities.<\/p>\n\n\n\n
\n\n\n\nBeyond Spreadsheets: In Silico Trials and Digital Twins<\/h2>\n\n\n\n
A broader vision is emerging around in silico clinical trials<\/strong>, where AI-enabled simulations complement or partially replace traditional control arms.<\/a><\/p>\n\n\n\n
- \n
- Virtual cohorts<\/strong>\u00a0are built from large real-world datasets and historical controls.<\/li>\n\n\n\n
- Digital twins<\/strong>\u2014patient-specific computational models combining imaging, genomics, and longitudinal data\u2014can simulate individual trajectories under different treatments.<\/a><\/li>\n\n\n\n
- These models can help:\n
- \n
- Refine inclusion criteria and endpoints.<\/li>\n\n\n\n
- Estimate expected effect sizes more accurately.<\/li>\n\n\n\n
- In some settings, reduce the required size of placebo\/control groups.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n
In oncology and dementia research, early work shows digital twins can predict survival or disease progression trajectories at the individual level<\/strong>, supporting both trial design and adaptive decision-making.<\/a><\/p>\n\n\n\n
Regulatory frameworks are still evolving, but the direction is clear: simulation will increasingly sit alongside traditional statistics as a core design tool.<\/strong><\/p>\n\n\n\n
\n\n\n\nWhere AI Meets Community Oncology and ACCC<\/h2>\n\n\n\n
The Association of Community Cancer Centers (ACCC) and its Community Oncology Research Institute (ACORI) have emphasized that trial design must reflect real-world patient populations and practice realities.<\/strong><\/a>\u200b<\/p>\n\n\n\n
AI-enabled design directly supports several ACCC priorities:<\/p>\n\n\n\n
- \n
- More representative eligibility:<\/strong>\u00a0Using real-world and community data to ensure criteria don\u2019t inadvertently exclude patients with common comorbidities or social risk factors.<\/li>\n\n\n\n
- Feasible protocols:<\/strong>\u00a0Simulation of visit schedules, lab requirements, and procedures to reduce site and patient burden.<\/li>\n\n\n\n
- Faster first-patient-in (FPI):<\/strong>\u00a0AI-assisted feasibility and reverse matching (trial-to-patient search) shorten the gap between trial activation and first enrollment.<\/a>\u200b<\/li>\n\n\n\n
- Diversity by design:<\/strong>\u00a0AI can help identify geographies and sites that serve underrepresented populations and simulate whether eligibility and operations will realistically allow these patients to enroll.<\/a><\/li>\n<\/ul>\n\n\n\n
CANCER BUZZ and ACCC Buzz have already highlighted how AI tools (like PRISM and others) are being piloted to match patients to trials and shorten activation-to-enrollment timelines<\/strong> in community settings. Extending this same mindset \u201cupstream\u201d into design makes trials more community-ready from day one.\u200b<\/a>\u200b<\/p>\n\n\n\n
\n\n\n\nCost and Productivity Impact<\/h2>\n\n\n\n
Timelines and cost are tightly coupled:<\/p>\n\n\n\n
- \n
- A Nature Digital Medicine\u2013cited analysis found that\u00a0AI-powered patient recruitment alone could cut trial costs by ~70% and expedite timelines by up to 40% in some settings<\/strong>, largely through better targeting and fewer failed screens.<\/a>\u200b<\/li>\n\n\n\n
- McKinsey reports that\u00a0combining classical AI\/ML with gen AI<\/strong>\u00a0for trial design, site selection, and operational decision-making has:\n
- \n
- Cut certain process costs by up to\u00a050%<\/strong>\u00a0(e.g., protocol and CSR drafting).<\/li>\n\n\n\n
- Accelerated some studies by\u00a0more than 12 months<\/strong>, when fully optimized across the lifecycle.<\/a>\u200b<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n
Even conservative scenarios\u201430% faster timelines and fewer amendments<\/strong>\u2014translate into:<\/p>\n\n\n\n
- \n
- Earlier regulatory submissions.<\/li>\n\n\n\n
- Lower burn per asset.<\/li>\n\n\n\n
- Faster patient access to new therapies.<\/li>\n\n\n\n
- Higher net present value (NPV) for the portfolio.<\/li>\n<\/ul>\n\n\n\n
\n\n\n\nPractical Limitations and Guardrails<\/h2>\n\n\n\n
Despite the promise, several cautions are essential:<\/p>\n\n\n\n
- \n
- Data bias:<\/strong>\u00a0If historical data under-represent certain populations or practice settings, AI-optimized designs can inadvertently \u201cbake in\u201d the same inequities. Using diverse, community-based data and explicitly auditing outputs for fairness is critical.<\/a>\u200b<\/li>\n\n\n\n
- Overfitting to history:<\/strong>\u00a0Past accrual problems may reflect outdated protocols or pre\u2013COVID patterns. Models must be regularly retrained and stress-tested.<\/li>\n\n\n\n
- Regulatory expectations:<\/strong>\u00a0In silico evidence and AI-derived design assumptions must be transparent, explainable, and aligned with FDA\/EMA guidance.<\/li>\n\n\n\n
- Human oversight:<\/strong>\u00a0As ACORI and ACCC leaders emphasize, AI tools should\u00a0augment\u2014not replace\u2014trial designers, investigators, and research staff.<\/strong><\/a>\u200b\u200b<\/li>\n<\/ul>\n\n\n\n
Human-in-the-loop review\u2014where oncology experts review AI-simulated scenarios, validate feasibility, and incorporate local context\u2014is non-negotiable.<\/p>\n\n\n\n
\n\n\n\nLooking Ahead: Gen AI Copilots for Trial Designers<\/h2>\n\n\n\n
Generative AI adds another layer: protocol and document copilots.<\/strong><\/p>\n\n\n\n
Recent work shows that LLMs fine-tuned on trial protocols can:<\/p>\n\n\n\n
- Overfitting to history:<\/strong>\u00a0Past accrual problems may reflect outdated protocols or pre\u2013COVID patterns. Models must be regularly retrained and stress-tested.<\/li>\n\n\n\n
- Data bias:<\/strong>\u00a0If historical data under-represent certain populations or practice settings, AI-optimized designs can inadvertently \u201cbake in\u201d the same inequities. Using diverse, community-based data and explicitly auditing outputs for fairness is critical.<\/a>\u200b<\/li>\n\n\n\n
- Accelerated some studies by\u00a0more than 12 months<\/strong>, when fully optimized across the lifecycle.<\/a>\u200b<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n
- McKinsey reports that\u00a0combining classical AI\/ML with gen AI<\/strong>\u00a0for trial design, site selection, and operational decision-making has:\n
- Feasible protocols:<\/strong>\u00a0Simulation of visit schedules, lab requirements, and procedures to reduce site and patient burden.<\/li>\n\n\n\n
- More representative eligibility:<\/strong>\u00a0Using real-world and community data to ensure criteria don\u2019t inadvertently exclude patients with common comorbidities or social risk factors.<\/li>\n\n\n\n
- Digital twins<\/strong>\u2014patient-specific computational models combining imaging, genomics, and longitudinal data\u2014can simulate individual trajectories under different treatments.<\/a><\/li>\n\n\n\n
- Virtual cohorts<\/strong>\u00a0are built from large real-world datasets and historical controls.<\/li>\n\n\n\n
- Estimate\u00a0screen fail rates and drop-out rates<\/strong>\u00a0for a proposed protocol.<\/li>\n\n\n\n
- Trained on thousands of historical trials, it achieved\u00a0mean absolute error of ~1.0 year<\/strong>\u00a0and RMSE of ~1.39 years in trial duration prediction, outperforming simpler baselines.<\/a>\u200b<\/li>\n<\/ul>\n\n\n\n
- TrialDura uses a\u00a0hierarchical attention transformer<\/strong>\u00a0over multimodal inputs\u2014disease area, intervention type, phase, region, eligibility complexity\u2014to predict\u00a0likely trial duration<\/strong>\u00a0and enrollment speed.<\/li>\n\n\n\n
- Optimistic enrollment forecasts<\/strong>\u00a0lead to missed milestones and repeated rescue amendments.<\/li>\n\n\n\n
![\"AI-Optimized](\"https:\/\/iicrs.com\/blog\/wp-content\/uploads\/2026\/02\/AI-Optimized-Trial-Design-Loop-_-IICRS-1024x576.jpeg\")
<\/figure>\n\n\n\n